Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Non-Current Debt (2020 - 2025)

Journey Medical (DERM) has disclosed Non-Current Debt for 6 consecutive years, with $19.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Debt fell 1.27% year-over-year to $19.5 million, compared with a TTM value of $19.5 million through Sep 2025, down 1.27%, and an annual FY2024 reading of $24.9 million, up 70.15% over the prior year.
  • Non-Current Debt was $19.5 million for Q3 2025 at Journey Medical, down from $21.4 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $24.9 million in Q4 2024 and bottomed at $9.9 million in Q1 2023.
  • Average Non-Current Debt over 5 years is $18.0 million, with a median of $19.6 million recorded in 2024.
  • The sharpest move saw Non-Current Debt crashed 32.81% in 2023, then surged 70.15% in 2024.
  • Year by year, Non-Current Debt stood at $15.0 million in 2021, then surged by 32.42% to $19.8 million in 2022, then decreased by 26.25% to $14.6 million in 2023, then surged by 70.15% to $24.9 million in 2024, then dropped by 21.48% to $19.5 million in 2025.
  • Business Quant data shows Non-Current Debt for DERM at $19.5 million in Q3 2025, $21.4 million in Q2 2025, and $23.1 million in Q1 2025.